product name Ampiroxicam
Description: Ampiroxicam (also known as CP 65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. Ampiroxicam (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. Ampiroxicam (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells.
References: J Natl Cancer Inst. 2006 Jun 21;98(12):855-68; Agents Actions. 1993 Jul;39(3-4):157-65.
447.46
Formula
C20H21N3O7S
CAS No.
99464-64-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 90 mg/mL (201.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
CP 65703
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19408685
| In Vitro |
In vitro activity: Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. Ampiroxicam (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. Ampiroxicam (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells. Kinase Assay: Panc-1 cells are plated in DME/F12 medium with 5% fetal bovine serum and treated on the next day with vehicle (0.1% DMSO) or various concentrations of Ampiroxicam. Cells are counted at the indicated times with a Coulter Z1 cell counter. Each experiment is done in triplicate, and results are expressed as means, with error bars representing 95% confidence intervals (CIs). Cell Assay: |
|---|---|
| In Vivo | Ampiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. Ampiroxicam inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. Ampiroxicam blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. Ampiroxicam (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats. Ultraviolet-A (UVA)-irradiated 1% Ampiroxicam sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% Ampiroxicam and 1% thiosalicylate (TOS). Concentration of Ampiroxicam is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam. |
| Animal model | Rats with adjuvant arthritis |
| Formulation & Dosage | Dissolved in 0.1% methylcellulose; 3.2 mg/kg; p.o. |
| References | J Natl Cancer Inst. 2006 Jun 21;98(12):855-68; Agents Actions. 1993 Jul;39(3-4):157-65. |
